Nantkwest (NASDAQ:NK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday. The brokerage presently has a $5.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 8.23% from the company’s current price.

According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “

Several other equities analysts have also recently issued reports on the company. Raymond James Financial reissued a “hold” rating on shares of Nantkwest in a report on Monday, December 11th. BidaskClub cut Nantkwest from a “sell” rating to a “strong sell” rating in a report on Friday, September 22nd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Nantkwest has a consensus rating of “Hold” and an average target price of $5.25.

Shares of Nantkwest (NASDAQ NK) traded up $0.18 during mid-day trading on Friday, hitting $4.62. The stock had a trading volume of 209,125 shares, compared to its average volume of 225,802. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Nantkwest has a fifty-two week low of $2.71 and a fifty-two week high of $8.45.

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Nantkwest by 155.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 25,579 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 71,444 shares during the period. SG Americas Securities LLC raised its holdings in Nantkwest by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 49,356 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 35,424 shares during the period. Russell Investments Group Ltd. acquired a new position in Nantkwest in the 3rd quarter worth about $139,000. California State Teachers Retirement System raised its holdings in Nantkwest by 58.1% in the 2nd quarter. California State Teachers Retirement System now owns 54,154 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 19,900 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Nantkwest by 1,110.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,572 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 25,295 shares during the period. 19.11% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Nantkwest (NK) Lifted to “Buy” at Zacks Investment Research” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/14/nantkwest-nk-lifted-to-buy-at-zacks-investment-research.html.

About Nantkwest

Get a free copy of the Zacks research report on Nantkwest (NK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.